BioCryst elects George Abercrombie to board
This article was originally published in Scrip
BioCryst Pharmaceuticals, a developer of novel small molecule drugs that block key enzymes involved in infectious diseases, inflammatory diseases and cancer, has elected George Abercrombie to its board of directors, while Dr Stephen Biggar has stepped down from the board. Mr Abercrombie served as CEO and President of the US arm of Roche from 2001-2009, and recently joined Tranzyme's board (scripintelligence.com, 22 September 2011). He is also chairman of the board at Brickell Biotech.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.